To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Compendia Collaborates with MDS Pharma Services to Deliver Oncology Drug Development Solution
Read time: Less than a minute
Compendia Bioscience has announced a strategic collaboration with MDS Pharma Services to deliver OncoPredictor, a novel solution for improved cancer drug development.
OncoPredictor combines MDS Pharma Services OncoPanel with Compendia Bioscience’s Oncomine’ for a solution that will provide guidance on patient groups most likely to respond to a new cancer therapy.
MDS Pharma Services OncoPanel service provides high content screening of up to 240 cancer cell lines to assess the cytotoxicity and chemotherapeutic potential of specific cancer drugs and drug combinations.
Compendia’s Oncomine, a database of cancer genomic profiles coupled with an analysis web application, provides genomic characterization and comparison of cancer cell lines to 2,000 disease signatures from more than 27,000 reference patients based on molecular, pathological and histological sub-types.
Through this collaboration, the OncoPredictor system will enable the analysis of drug sensitivity and resistance of novel drugs and drug combinations as well as the identification of associations with both disease sub-types and underlying tumor biology.
The solution will be delivered as a stand-alone, end-to-end service and will not require a license to any of Compendia’s Oncomine offerings.
OncoPredictor combines MDS Pharma Services OncoPanel with Compendia Bioscience’s Oncomine’ for a solution that will provide guidance on patient groups most likely to respond to a new cancer therapy.
MDS Pharma Services OncoPanel service provides high content screening of up to 240 cancer cell lines to assess the cytotoxicity and chemotherapeutic potential of specific cancer drugs and drug combinations.
Compendia’s Oncomine, a database of cancer genomic profiles coupled with an analysis web application, provides genomic characterization and comparison of cancer cell lines to 2,000 disease signatures from more than 27,000 reference patients based on molecular, pathological and histological sub-types.
Through this collaboration, the OncoPredictor system will enable the analysis of drug sensitivity and resistance of novel drugs and drug combinations as well as the identification of associations with both disease sub-types and underlying tumor biology.
The solution will be delivered as a stand-alone, end-to-end service and will not require a license to any of Compendia’s Oncomine offerings.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
